Comorbidities and Diabetes Type 2

Author(s):  
Chinedu I. Ossai ◽  
Nilmini Wickramasinghe ◽  
Steven Goldberg

The prevalence of diabetes type 2 among the population and the increasing rate of new diagnoses as well as other co-morbidities make it imperative that we develop a richer understanding of type 2 diabetes. An Australian survey of diabetes type 2 people for different co-morbidities was carried out to obtain information about the possible connections of the co-morbidities with type 2 diabetes. The analysis is done with the logit model and Pearson's chi-square and the results indicate that gender, age of the patients, and the duration of the diabetes type 2 diagnosis play a significant role in the exposure of individuals to different comorbidities. The influence of the duration of diagnosis and age of the patients is limited in comparison to the gender, which has females at a very high risk of developing the studied co-morbidities compared to males. The findings can improve diabetes type 2 management to boost high quality, proactive, and cost-effective caregiving for the patients.

Author(s):  
Mulia Mayangsari

 Individuals who have a family history oftype 2 diabetes mellitus (DM) have a highrisk for type 2 diabetes. Type 2 diabetescan be prevented by improving modifiablerisk factors, supported by self-awareness,perceptions and attitudes of individualswho have a high family history of DM. Thisstudy used a qualitative phenomenologicaldesign. A Purposive Sampling techiniquewas applied to determine individuals whohad parents with type 2 diabetes. Nineindividuals participated in this study. AQualitative content analysis with Collaiziapproach used as a data analysis method.The main themes depicted individuals selfawareness,perceptions, & attitudes were:denials that diabetes caused by heredityfactors; misperception about diabetes;“traditional modalities” as a preventionmeasurement toward type 2 diabetes; andDM is perceived as a “threatening disease”.Further study is needed to examine indepth the themes that have been identifiedon the number of participants are morenumerous and varied.


2020 ◽  
Vol 2 (1) ◽  
pp. 12-16
Author(s):  
Fennoun H ◽  
Haraj NE ◽  
El Aziz S ◽  
Bensbaa S ◽  
Chadli A

Introduction: Hyperuricemia is common Type 2 diabetes at very high cardiovascular risk. Objective: Evaluate the relationship between hyperuricemia and diabetes type 2, and determine its predictive factors in this population. Patients and Methods: Retrospective study cross including 190 patients with diabetes type 2 hospitalized Service of Endocrinology of CHU Ibn Rushd Casablanca from January 2015 to December 2017. Hyperuricemia was defined as a serum uric acid concentration> 70 mg/L (men) and> 60 mg/L (women). The variables studied were the anthropometric measurements), cardiovascular factors (tobacco, hypertension, dyslipidemia), and degenerative complications (retinopathy, neuropathy, kidney failure, ischemic heart disease). The analyzes were performed by SPSS software. Results: Hyperuricemia was found in 26.5% of patients with a female predominance (76%), an average age of 55.9 years, and an average age of 12.4ans diabetes. The glycemic control was found in 84.6% of cases with mean glycated hemoglobin 8.6%. Factors associated al hyperuricemia were the blood pressure in 86% (p <0.05), dyslipidemia in 76.3% of cases (p <0.001) with hypertriglyceridemia in 48.3% of cases (p <0.02), and a hypoHDLémie 28% (p <0.001). The age, obesity, smoking, and glycemic control were associated significantly n al hyperuricemia. The research of degenerative complications of hyperuricemia has objectified renal impairment (GFR between 15 and 60ml / min) chez47% (p <0.001), it was kind of moderate in 35.8% (p <0.01) and severe in 5.1% (p <0.02), ischemic heart disease was found in 34% of cases (p <0.01). Conclusion: In our study, hyperuricemia in type 2 diabetes is common in female patients, especially with hypertension, dyslipidemia, and renal failure. Other factors such as age, obesity, smoking is not associated with hyperuricemia in type 2 diabetics.


2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Basilio Pintaudi ◽  
Alessia Scatena ◽  
Gabriella Piscitelli ◽  
Vera Frison ◽  
Salvatore Corrao ◽  
...  

Abstract Background The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care, with particular regard to cardiovascular risk factors. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD Annals initiative. Patients with T2D were stratified by cardiovascular risk. General descriptive indicators, measures of intermediate outcomes, intensity/appropriateness of pharmacological treatment for diabetes and cardiovascular risk factors, presence of other complications and overall quality of care were evaluated. Results Overall, 473,740 subjects with type 2 diabetes (78.5% at very high cardiovascular risk, 20.9% at high risk and 0.6% at moderate risk) were evaluated. Among people with T2D at very high risk: 26.4% had retinopathy, 39.5% had albuminuria, 18.7% had a previous major cardiovascular event, 39.0% had organ damage, 89.1% had three or more risk factors. The use of DPP4-i markedly increased as cardiovascular risk increased. The prescription of secretagogues also increased and that of GLP1-RAs tended to increase. The use of SGLT2-i was still limited, and only slightly higher in subjects with very high cardiovascular risk. The overall quality of care, as summarized by the Q score, tended to be lower as the level of cardiovascular risk increased. Conclusions A large proportion of subjects with T2D is at high or very high risk. Glucose-lowering drug therapies seem not to be adequately used with respect to their potential advantages in terms of cardiovascular risk reduction. Several actions are necessary to improve the quality of care.


2020 ◽  
Author(s):  
Ibiyemi Ilesanmi ◽  
George Tharakan ◽  
Kleopatra Alexiadou ◽  
Preeshila Behary ◽  
Haya Alessimii ◽  
...  

<b>Objective:</b> Roux-en-Y gastric bypass (RYGB) is an established treatment for type 2 diabetes. The study objective was to establish RYGB’s effects on glycaemic variability (GV) and hypoglycaemia. <p><b>Research Design and Methods:</b> Prospective observational study of 10 participants with pre-diabetes/Type 2 diabetes undergoing RYGB, studied before surgery (Pre), 1 month (1m), 1 year (1y) and 2 years (2y) post-surgery with continuous glucose measurement (CGM). A mixed meal test (MMT) was performed at Pre, 1m and 1y. [ClinicalTrials.gov NCT01945840]</p> <p><b>Results:</b> After RYGB, mean CGM glucose fell (at 1m, 1y and 2y), and GV increased (at 1y and 2y). Fifty percent (5/10) of participants exhibited a percentage time in range <3.0 mmol/L [54 mg/dl] (%TIR<3.0) greater than the consensus target of 1% at 1y or 2y. Peak glucagon-like peptide-1 (GLP-1) and glucagon area-under-curve (AUC) during MMT were respectively positively and negatively associated with contemporaneous %TIR<3.0. </p> <b>Conclusions:</b> Patients undergoing RYGB are at risk of developing post-bariatric hypoglycaemia due to a combination of reduced mean glucose, increased GV and increased GLP-1 response.


Open Heart ◽  
2017 ◽  
Vol 4 (2) ◽  
pp. e000656 ◽  
Author(s):  
James J DiNicolantonio ◽  
Jaikrit Bhutani ◽  
James H OKeefe ◽  
Catherine Crofts

2017 ◽  
Vol 43 (3) ◽  
pp. 292-294 ◽  
Author(s):  
S. Hassoun ◽  
M. Al-Atrash ◽  
M. Alkasim ◽  
Z. Dabbous ◽  
O. Mujahed ◽  
...  

2018 ◽  
pp. 36-39
Author(s):  
M.O. Pavlovska ◽  

The objective: was to compare the efficacy of complex methods of treating climacteric syndrome in patients with concomitant type 2 diabetes mellitus (DM) by analyzing hormonal parameters before and after complex therapy using antihomotoxicological drugs. Materials and methods. We examined 58 patients aged 45-55 years with a climacteric syndrome on the background of a 2-type diabetes mellitus. Women of the 1st group (n = 28) received only basic therapy according to the National Consensus for the management of patients in menopause with concomitant DM of type 2. Women of the 2nd group (n = 30) were treated with antihomotoxicological drugs against the background of basic therapy. Results. The proposed complexes positively influenced the hormonal state of patients, and also reduced the severity of climacteric syndrome and psychoemotional component. More effective was a complex that included antihomotoxicological agents, which is confirmed by the dynamics of hormonal parameters. Conclusion. From the clinical point of view, the obtained results give grounds to recommend these complexes for the correction of hormonal disorders in women with menopausal disorders on the background of type 2 diabetes mellitus. Key words: climacteric syndrome, diabetes type 2, base therapy, antihomotoxicological agents.


Sign in / Sign up

Export Citation Format

Share Document